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In 4ssociation for Molecular Pathology et al.
v. US. Patent and lrademark Office, et al., the
U.S. District Court for the Southern District
of New York invalidated a claim to patent
genetically developed material on the basis
that "[t]he patents issued by the [United States
Patent Office] are directed to a law of nature
and were therefore improperly granted."1 The
court's decision pertained to Myriad's claims
to patent isolated DNA for breast cancer
susceptibility genes I and 2, "BRCA 1/2,"
and applicable processes. Rejecting Myriad's
patent theory, the court stated that "the patents
at issue directed to 'isolated DNA' containing
sequences found in nature are unsustainable."
Although the Federal Circuit reversed in part
the district court's decision, the case could still
be appealed to the Supreme Court.) At that
point, progress in commercial patent-centric
genetic research is at risk. If the Supreme Court
reverses the Federal Circuit Court decision,
very few incentives will exist for commercial
patient-centric genetic research. 4
In light of the Association for Molecular
Pathology decision, the Patient Protection
Affordable Care Act (PPACA) has important
implications for commercial personalized
research. Specifically referencing genetic
research and personalized medicine in several
provisions, PPACA offers several guarantees to
ensure the progress of commercial personalized
medical research.5
This paper will provide the legal framework
for patents and genetic research, focusing on
the applicable constitutional provisions, federal
statutes, and federal cases. It will also discuss
PPACA's provisions and its potential to rescue
commercial genetic research if the Federal
Circuit's decision in Association for Molecular
Pathology is reversed by the Supreme Court.
L, Patecints ad eneicResearch ,
AU.S Constitution
Congress is authorized by the U.S. Constitution
to enact legislation, "To promote the Progress
of Science and useful Arts, by securing for
limited Times to Authors and Inventors the
exclusive Right to their respective Writings and
Discoveries."6
B. Federal Statutes
As background, it is noted that:
The idea of having the federal government
encourage authorship and invention
through the grant of temporary monopolies
was derived by the framers of the
Constitution from the English experience.
James Madison, in the Federalist Papers.,
in advocating that the national government
have the power to provide therefor,
specifically alluded to the recognition
of copyright in Britain, beginning his
argument with the statement: "The utility
of this power will scarcely be questioned.""
Ihe Patent Act of 1793. which replaced the
original Patent Act of 1790,s defined patentable
subject matter and provided:
That when any person or persons, being a
citizen or citizens of the United States, shall
allege that he or they have invented any
new and usefid art, machine, manufacture
or c omposition of matter or an) new and
usefud iniproviement on any art, machine,
manufacture or composition of matter
[emphasis added], not known or used
hefore the application, and shall present a
petition to the Secretary of State. signifying
d desire of obtaining ani exclusivet property
in the same, and praying that a patent may be granted therefor,
it shall and may be lawful for the said Secretary of State, to
cause letters patent to be made out in the name of the United
States.9
As the U.S. Supreme Court stated in Diamond . Chakrabarty
"The Act embodied [Thomas] Jefferson's philosophy that
'ingenuity should receive a liberal encouragement. '"
In 1952. the most recent substantive revisions were enacted." The
Patent Act of 1952, which applies to the analysis in this paper,
is codified in Title 35 of the United States Code and provides in
pertinent part:
§ 100. Definitions: When used in this title unless the context
otherwise indicates-
(a) The term "invention" means invention or discovery.
(b) The tenn "process" means process, art or method, and
includes a new use of a know n process, machine, manufacture,
composition of matter, or material.
§ 101. Inventions patentable: Whoever invents or discovers
any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement
thereof, may obtain a patent therefor, subject to the conditions
and requirements of this title.
§ 102. Conditions for patentability; novelty and loss of right
to patent: A person shall be entitled to a patent unless-(a)
the invention was known or used by others in this country,
or patented or described in a printed publication in this or a
foreign country, before the invention thereof by the applicant
for patent, or (b) the invention was patented or described in a
printed publication in this or a foreign country or in public use
or on sale in this country, more than one year prior to the date
of the application for patent in the United States, or (c) he has
abandoned the invention....
§ 103. Conditions for patentability; non-obvious subject
matter (a) A patent may not be obtained though the invention
is not identically disclosed or described as set forth in section
102 of this title, if the differences between the subject matter
sought to be patented and the prior art are such that the subject
matter as a whole would have been obvious at the time the
invention was made to a person having ordinary skill in the
art to which said subject matter pertains.12
Diamond v. Chlakrabarty
In 1972, the microbiologist Ananda Mohan Chakrabarty filed
a patent application consisting of thirty-six claims that related
to Chakrabarty's insvention of a bacterium that vvas capable of
dissolsving components of crude oil.'3 The commercial value
for the treatment of oil spills with Chakrabarty's invention
was undisputed. Additionally, there was no naturally existing
bacterium that demonstrated the same impact durine the
treatment of oil spills.14 As the U.S. Supreme Court noted, the
existing method for treating oil spills consisted of a combination
of naturally occurring bacteria, each of which would degrade a
single component of the oil.'5 C hakrabarty 's bacterium, however,
proved to be more efficient at controlling oil spills because it
broke down multiple components of the oil rather than a single
component.16
Chakrabarty's claims consisted of three components. The first
component was the process; the second was the "carrier" or
water surface vehicle, e.g., straw; and the third was the actual
bacterium.1 The patent examiner who reviewed Chakrabarty's
application granted the first two components and rejected the
third on the following grounds: "(1) that micro-organisms are
'products of nature,' and (2) that as living things they are not
patentable subject matter under 35 U.S.C. 10l."
The Court further clarified the issue by explaining that it must
decide whether the micro-organism constitutes a "manufacture"
or a "conposition of matter" within the meaning of the statute.9
After considering various judicial and treatise-derived definitions
of the terms "manufacture" and "composition of matter," the
Court stated, "In choosing such expansive terms as 'manufacture'
and 'composition of matter,' modified by the comprehensive
any,' Congress plainly contemplated that the patent laws would
be given wide scope."' 0 Further, after discussing the Patent Act
of 1793 and the authorship of Thomas Jefferson, the Court added
that the legislative history supported a broad interpretation of the
statute)1
The Court, however, stated that section 10 1 is not unlimited. For
example:
[A] new mineral discovered in the earth or a new plant found
in the wild is not patentable subject matter. Likewise, Einstein
could not patent his celebrated law that E mc2: nor could
Newton have patented the lass of gravity. Such discoveries
are "manifestations of . .. nature, free to all men and reserved
exclusively to none." 22
Nevertheless, the Court sustained Chakrabarty's patent
application, explaining that Chakrabarty's bacterium had
"markedly different characteristics" from any naturally made
bacterium, and noted its "potential for significant utility" 23
Bilki v. Kappos
On writ of ccrtiorari from the Federal Circuit, the Suprcme Court
reviewed a patent claim that consistcd of a business application.24
Thc patent application included txvo claims that consisted of
a procedure designed to assist buyers and sellers in protecting
themselves from price fluctuations in commodities that are
connected to the energy market. Both claims together consist of
procedures and a mathemafical formula.25
The patent examiner reviewing the application rejected the patent
application on the grounds that the claim is an attempt to patent
a mere abstract idea that does not have any specific limitation
to practical application.26 The Board of Patent Appeals and
Interference and Federal Circuit affirmed. The Board stated, "The
application involved only mental steps that did not transform
physical matter and was directed to an abstract idea."27
Citing C'hakrabarty, the Court began its analysis by noting three
exceptions to section 101's patent-eligibility principles: "laws
of nature, physical phenomena, and abstract ideas." 8 The patent
claims in this case may include methods of doing business, which
might be considered a "process" as the term "method" fell within
100(b)'s definition of "process."29 The Court went on to say, "In
searching for a limiting principle, this Court's precedents on the
unpatentability of abstract ideas provide useful tools." 0
Facilitating this theory, the Court rejected the patent claims because
it did not agree with patenting "abstract ideas."" Continuing, the
Court cautioned against the ramifications of patenting risk hedging
in this context, claiming that it would "effectively grant a monopoly
over an abstract idea." 32 Here, the abstract idea was a mathematical
formula.
Prometheus Laboratories v. -Mayo
The Supreme Court remanded Prometheus (M1a'yo v. Prometheus)
to the Federal Circuit for re-adjudication in light of the Supreme
Court's decision in Bilski, particularly the portion of the Bilski
holding that rejected the "machine-or-transformation test" as the
exclusive test for determining whether process-type claims are
patent eligible.] The claimed patents were designed to maximize
their "therapeutic efficiency" and minimize toxicity.34
Rather than reject the "machine-or-transformation" test, the Federal
Circuit in Prometheus explained that the test could be used, as set
forth by the Supreme Court in Bilski, as an "investigative tool"
for deciding wxhether certain inventions fall under section 101.
Additionally, the Federal Circuit noted that the Supreme Court
moderated the "abstract idea" limitation, stating, "The Supreme
Court has also established that while a law of nature, natural
phenomenon, or abstract idea cannot be patented, 'an application
of a law of nature or mathematical formula to a known structure or
process may well be deserving of patent protection."' 3 6
The Federal Circuit, in the concluding stage of its analysis,
explained that patent eligibility in this case depended upon whether
Prometheus's claims were based on a "natural phenomenon" or "a
particular application of that phenomenon>" T he Federal Circuit
decided in favor of Prometheus's claims." Concluding, the Federal
C ircuit found that Promtetheus' patents met the transforimation test
prong of the machine-or-transforination test because they changed
the state of an article]39
Assoc/ation for Molecular Pathology v US. Patent & Trademark Office
T he plaintiffs in As soc/at/on for Vloleeular Pathology challenged
as inv alid fifteen patent claims in seven patents that pertain to
human BRCAI and BRCA2 genes, or breast cancer susceptibility
genes I and 2 (collectively referred to as "BRCAI/2").40 The
plaintiffs challenged patent claims on isolated DNA, which
contained the BRCA1/2 gene sequences, and patent claims on
the methods used to analyze the BRCAI/2 gene sequences. 41 The
court determined the central issue was whether the comparison of
isolated human genes is patentable.42
Breast cancer is the most commonly diagnosed cancer in the
world. It is also one of the highest causes of cancer-related death
among women.43 It is important to consider BRCA1/2 mutations
in providing clinical care for breast and ovarian cancer.44 The hope
is that testing will inform a woman of her risk and help clinicians
determine how to prevent and/or treat the cancer.45 As the result of
its research and development, Myriad, the patentee, marketed the
BRCA Analysis Rearrangement Test (BART), which detects the
majority of large rearrangement mutations in BRCA1/2.46
Prefacing its decision, the district court quoted Justice Breyer, who
had wx ritten that "sometimes too much patent protection can impede
rather than 'promote the Progress of Science and useful Art,' the
constitutional objective of patent and copyright protection."47 The
court acknowledged that Supreme Court precedent has established
that patents cannot apply to products of nature unless a change results
in a fundamentally new product."48 Taking this into consideration,
the court held that the structural and functional differences cited
by Myriad do not render isolated BRCAI/2 "markedly different"
from native BRCAl/2, thereby designating the isolated BRCA1/2
an unpatentable product of nature.49
D. Discussion of Cases
The Federal Circuit essentially following its analysis of section 101
in Prometheus50 and reversed the district court.5 In its decision,
the Federal Circuit did not follow Bilski. If the Supreme Court
overturns the Federal Circuit (assuming the case is appealed to
the Court), the Supreme Court's decision would be based on the
reasoning that isolating the BRCAl and BRCA2 genes would
merely constitute or equate to "manipulat[ing] [an] abstract
idea,"52 absent any change or transformation, retaining only the
abstract nature of an "idea."53 This result would follow a narrow
interpretation of the Supreme Court's decision in Chakrabarty.54
The Chakrabartj Court, however, relied upon the writings of
Ihomas Jefferson.5
A. Baekground Coimercialization of Genetic Research
The National Institutes of Ilealth (NIHI) published Best Practices for
the Licensing of Genomnic Inventions in 200556 and iecommended
that, if possible, non-exclusive licensing should be used.57 Exclusise
licensing, however, is appropriate when private partners are needed
to drive research and development.5 Additionally, in 2006. the
National Research C ouncil recommended educational and non-
commercial patent infringement exemptions and judicial deference
to patents related to genetic research and public health. 9
a. Overview
The following PPACA provisions, as stated below, target genetics
or personalized medicine:
* Section 3011 provides for "patient-centeredness of health
care."
o Section 3113 provides for "Treatment of certain complex
diagnostic laboratory tests," which includes an analysis
of "gene protein expression, topographic genotyping, or a
cancer chemotherapy sensitivity assay."
* Section 4103 provides for "Medicare coverage of annual
wellness visit providing a personalized prevention plan."
* Section 6301, "Patient-centered outcomes research,"
provides, in part, that "medical, treatmentsc, ervices, and
items," include "drugs and biologicals."
What is the link betw een genetics research and individual medical
treatment? What does the term "personalized medicine" mean?
According to the Mayo Clinic, pharmacogenomics is the link
between prescription drugs and genetic research. It potentially
allows physicians to predict how certain medicines will affect
individuals before actually taking the drugs, which would allow
physicians to better treat patients.60
Researchers at the Howard Hughes Medical Institute, Duke
University, and the Koo Foundation-Sun Yat Sen Cancer Center
addressed these concepts in greater detail in the context of
researching breast cancer. 6 Generally, the authors opined that "the
value in genomic data is its scale and complexity; when combined
with clinical and demographic factors, multiple forms of molecular
data provide inforiiiation that has the potential to identify unique
characteristics of the individual and so lead to customized health
care strategies."62
The concept is apparently straightforward; however, developing
efficient analytic methods to capture and integrate this data into
a personalized diagnostic setting is the current challenge for
researchers.63 For example, in the treatment of cardiovascular
disease, many drugs are available. However, typically only a few
of the drugs actually work for any particular patient. Additionally,
patients often experience negative side effects. The goal is to
identify which drug vorks for a particular person, vithout negatie
side effects, within the context of an indixvidualized treatment
plan.64
Regarding breast cancer, the researchers noted that niany women wxho
are diagnosed w ith early stage breast cancer undergo chemotherapy;
howvever, womien who are determined to be low-risk cases also
frequently undergo chemotherapyt6 Genetic research has the
potential of targeting or personalizing the treatment of breast cancer
and reducing the incidents of unnecessarily insasisve treatments,
such as chemotherapy. Researchers hasve profiled gene expression
characteristics that relate to how cancer tumors behave.66 Using this
information to predict if an individual will develop a disease would
help clinicians create personalized treatment plans for patients.6
b. Does the PPICA rescue commercial genetic research ifthe
Pet/eral Circuit s reversal of the district court : decision in
Association fbr Molecular Pathology is overturned?
How is the federal government planning to spend money in the 2012
fiscal year in connection with personalized medicine? The answer
to this question creates the path to determining whether the PPACA
will rescue genetic research.
. Budgetary clues
The 2012 Budget for the Department of Health and Human
Services (HHS) includes two primary references to the PPACA
and personalized medicine.68 First, the 2012 HHS budget contains
$620 million for the Patient-Centered Outcomes Research Institute
(PCORI), a not for profit non-governmental entity that was created
by the PPACA. 69 The PCORI was created to "help get relevant,
high quality information to patients, clinicians and policy-makers
so that they can make informed health care decisions."7 0 The 2012
HHS Budget, which relates to the PPACA, includes within the $620
million, $30 million from the Irust Fund, to be used for research on
core patient-centered health. 71 In total, when department-wide 2012
funding is considered to include all sources, including the American
Recovery and Investment Act, a total of $1.1 billion is allocated
although not filly budgeted, for patient-centered health research"
comparative effectiveness.72
Second noting that section 6301 of the PPACA, which provides
for "[p]atient-centered outcomes research," includes "medical
treatments, services, and items" such as "drugs and biological"' the
2012 HHS budget contains the following provision:
Modifji Length of Exclusivity to Facilitate Faster Development
of Generic Biologics: The Affordable Care Act created a
pathway for the FDA approval of generic biologics, providing
a 12 year exclusivity period. This proposal would shorten the
exclusivity period from 12 to 7 years.
Additionally, although not directly linked in the 2012 HHIIS budget
to the PPACA, the National Institutes of Health (NIIH) was allocated
$32 billion, part of which is intended for genetic research.7
According to the HHS, breakthroughs in determining what causes
diseases and liow to create better therapeutics can be found using
genomic research.
According to the Hlouse Report 708, section 4103 proxvides for
wellness xvisits cach year. comprehensisve health risk assessments
and persoiialized prevention plans.76 Additionally, the House
Report stated that provisions in lithe IV of PPACA relate to disease
prevention and public health and along with section 4103 prov ide
for Animal Wellness Visits and personalized prev ention plans under
Medicare.
in recent years and have shown that it is possible to identify the
The House Report explained, regarding section 6301, that a would not be a direct substitute for prixate venture capital.
Patient-Centered Outcomes Research Institute, a not for profit non- Government funding, as required by the PPACA and evidenced
governmental entity, will be established in accordance with this the 2012 HHS budget, could form a precursor to eventual privat
section.'- Additionally, under section 6301, funding will be given to investment, indirectly offsetting the impact of these theories.A
the Agency for Health Research and Quality, an entity established to partial rescue for commercial personalized medicine and genetic
publish the Institute's findings and train researchers in comparative rescarch, courtesy of the PPACA, xould likely axait Myriad and
research methods.79 similarly situated piiate enteipiises.
According to Senate Report 112-11, the Senate Finance Committee,
on April 21, 2009, conducted a roundtable to discuss "Reforming
America's Health Care Delivery System." The discussion focused
on possible methods to increase the availability of patient-centered,
affordable health care services. 80 The roundtable was preceded by
a February 25, 2009 report from the Congressional Budget Office
(CBO) regarding CBO reports that included "provisions aimed at
expand[ing] coverage or health care affordability."
2. Discussion of budgetary and legislative history considerations
The 2012 111S budget contains specific funding allocations for
private research related to patient-centered outcomes. Department-
wide 2012 funding is $1.1 billion, and as part of this amount,
$620 million is dedicated to PPACA-related patient-centered
outcomes through the non-governmental PCORI.82 Additionally,
the HHS 2012 budget contains resources that pertain to the PPACA
requirement to reduce from twelve to seven years the exclusivity
period for generic biologics, which relates to the PPACA section
6301 provisions that mandate patient-centered outcomes research
to include "drugs and biologicals." 3
The legislative history of the PPACA suggests an open legislative
path to patient-centered and non-governmental research. As a
Senate report indicated, "[PPACA section 6301] provides funding
for the Institute [PCORI]."84 Prior to enactment of the PPACA in
2010, congressional committees conducted hearings and roundtable
meetings during wx hich presenters endorsed programs and funding
for patient-centered, affordable health care services.
The 2012 HHS budget and House and Senate reports suggest that
both the legislative and executive branches view the PPACA as
mandating support for non-governmental patient-centered health
care research. Does this include for-profit, commercial research? Or
is PPACA support for patient-centered health care research limited
to the not-for-profit arena?
Goxvernent funded research that is related to patient-centered
heahlh care outcomes, as mandated by the PPACA, will exentually
track and find its xvay to the private sector, both not-for-profit
and for-profit. As a Senate report discussed, the PPACA allocates
funding to both PCORI and the Agency for Health Research and
Quality, alloxxing for the training of researchers in comparativ e
effnctixmentssinethodslyndffhettisseminationctfofesearchthindings 86
The PPACA would provide some relief to offset the theories
propounded by the district court and Federal Circuit dissents in
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